

Ref. No: FOI2334  
Date: 30/01/2026  
Subject: Treatment of Waldenström macroglobulinaemia (WM) & Marginal zone lymphoma (MZL)

## REQUEST

1. Does your Trust treat patients for the two following conditions?

Yes/No

**Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)**

**Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)**

If yes:

1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions?

**Waldenström macroglobulinaemia (WM)**

**Marginal zone lymphoma (MZL)**

1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials.

**Waldenström macroglobulinaemia (WM)**

**Marginal zone lymphoma (MZL)**

Please skip 1c to question 2 and 3.

If no:

1c. Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions?

Thank you for answering this survey.

2. How many patients (and new patients\* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?

<b>Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)</b>		
<b>Regimen</b>	<b>Total Patients</b>	<b>New Patients*</b>
Fludarabine, cyclophosphamide and rituximab (Known as FCR)		
Bendamustine in combination with rituximab (Known as		

BR)		
Ibrutinib		
Ibrutinib in combination with rituximab		
Zanubrutinib		
Acalabrutinib		
Chemotherapy (Other than the listed regimens)		
Wait and watch - no active treatment and monitoring only		
Any other treatment (Other than the listed regimens)		

\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

3. How many patients (and new patients\* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?

<b>Marginal zone lymphoma (MZL) (ICD-10 C83.0 &amp; C88.4)</b>		
<b>Regimen</b>	<b>Total Patients</b>	<b>New Patients*</b>
Bendamustine in combination with rituximab (Known as BR)		
Chlorambucil in combination with rituximab (Known as CR)		
R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)		
R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)		
Zanubrutinib		
Stem Cell Transplant		
Wait and watch - no active treatment and monitoring only		
Any other treatment (Other than the listed regimens)		

\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

## RESPONSE

1. Does your Trust treat patients for the two following conditions?

Yes

**Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)**

**Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)**

If yes:

1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions?

**Waldenström macroglobulinaemia (WM) - 17**  
**Marginal zone lymphoma (MZL) - 33**

1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials.

**Waldenström macroglobulinaemia (WM)**  
**Marginal zone lymphoma (MZL)**

No

Please skip 1c to question 2 and 3.

If no:

1c. Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions?

**Clatterbridge Cancer Centre or The Christie**

Thank you for answering this survey.

2. How many patients (and new patients\* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?

<b>Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)</b>		
<b>Regimen</b>	<b>Total Patients</b>	<b>New Patients*</b>
Fludarabine, cyclophosphamide and rituximab (Known as FCR)	-	-
Bendamustine in combination with rituximab (Known as BR)	<5	<5
Ibrutinib	<5	-
Ibrutinib in combination with rituximab	-	-
Zanubrutinib	7	<5
Acalabrutinib	-	-
Chemotherapy (Other than the listed regimens)	<5	<5
Wait and watch - no active treatment and monitoring only	-	-
Any other treatment (Other than the listed regimens)	-	-

\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

3. How many patients (and new patients\* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?

<b>Marginal zone lymphoma (MZL) (ICD-10 C83.0 &amp; C88.4)</b>		
<b>Regimen</b>	<b>Total Patients</b>	<b>New Patients*</b>

Bendamustine in combination with rituximab (Known as BR)	<5	<5
Chlorambucil in combination with rituximab (Known as CR)	--	-
R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)	<5	<5
R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)	<5	<5
Zanubrutinib	6	<5
Stem Cell Transplant	-	-
Wait and watch - no active treatment and monitoring only	8	8
Any other treatment (Other than the listed regimens)	13	<5

\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.